New hope for rare skin cancer: drug combo trial launches
NCT ID NCT06673628
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a combination of two drugs, pembrolizumab and lenvatinib, in 38 people with a rare and aggressive skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if this treatment can shrink tumors and improve outcomes. Participants will receive the drugs for up to two years, with regular monitoring for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and lenvatinib
- What this could lead to
- If it works, this could offer a new treatment option for a rare skin cancer that currently has a very low survival rate.
- What could go wrong
- This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. The combination may cause side effects and may not shrink tumors in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, University of Miyazaki Hospital
RECRUITINGMiyazaki, Japan
-
Keio University Hospital
RECRUITINGTokyo, Japan
-
Nagoya City University Hospital
RECRUITINGNagoya, Japan
-
National Cancer Center Hospital
RECRUITINGTokyo, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Japan
-
University Hospital Kyoto Prefectural University of Medicine
RECRUITINGKyoto, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.